
8th International Electronic Conference on Medicinal Chemistry
Part of the International Electronic Conference on Medicinal Chemistry series
1–30 Nov 2022
Medicinal Chemistry, Pharmaceuticals, Drug
- Go to the Sessions
- Event Details
On behalf of the conference team of the 8th International Electronic Conference on Medicinal Chemistry, we would like to thank you for your participation by sending your contributions, being posters, slideshows or flash communications. We hope you've enjoyed it!
List of accepted submissions (254)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-066014 | Small molecule inhibitors of bacterial quorum sensing |
![]() |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Quorum sensing is a bacterial mechanism that is essential in the pathogenesis of many infections, such as P. aeruginosa. These infections are strongly influenced by specific quorum sensing molecules, such as Autoinducer-2 (AI-2). AI-2 binds to quorum sensing receptors within bacteria leading to the up-regulation of virulence genes that cause biofilm formation and toxin production. Naturally-occurring brominated furanones isolated from the marine algae Delisea pulchra were previously found to possess properties which inhibited bacterial quorum sensing in AI-2 sensitive species. The aim of this work was to create a series of novel halogenated furanones which can act as quorum sensing inhibitors of AI-2. Based on the lead from Delisea pulchra, a library of compounds was synthesised via the functionalisation of gem-dibromoolefin and gem-dichloroolefin intermediates using palladium-catalysed couplings, namely Suzuki and Sonogashira reactions. These compounds were subsequently evaluated for their effects on biofilm formation in selected microbes. Several molecules were confirmed to be highly effective biofilm inhibitors in multiple pathogens, including P. aeruginosa and C. albicans. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-066297 | YAMACS: A graphical user interface of GROMACS |
,
,
Luigi Di Biasi ,
|
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Molecular dynamics (MD) is a powerful tool used to study the evolution of molecular systems and predict their properties from the inherent interactions. GROMACS is a famous tool for MD and developed as open-source software. GROMACS is run from the command line with user-provided configuration files. However, the absence of a graphical user interface (GUI) of GROMACS and proper protocol to develop the input files (Ex: itp files, topology files, etc.) prevent the researcher from visualizing the MD trajectory in a real-time manner as well as addressing the structural problem. This issue was addressed by developing a graphical user interface of GROMACS as plugins for YASARA molecular graphics suite, called YAMACS. YAMACS is an open-source project and is available on GitHub (https://github.com/YAMACS-SML/YAMACS). The tool can perform MD simulations for protein, protein-ligand complex, membrane–protein complex, membrane-protein complex, and small molecule system. Easily YAMACS automatizes several steps of input file preparation and allows visualizing MD trajectory in real-time. At this conference, I will present the application of YAMACS to simulate the complex sphingomyelin/POPC embedded in a membrane of POPC. I will also introduce a collaborative platform to create an open community of users and developers, extend the functionalities of YAMACS and improve the quality of computational drug design studies. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-066755 | Molecular Docking, PASS Prediction, Pharmacokinetic and Toxicity studies of Focal Adhesion Kinase inhibitors | , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Drug discovery relies on computational medicinal chemistry for designing and identifying new drug-like chemicals, predicting properties and pharmacological activities of molecules, and optimizing lead structures. Focal Adhesion Kinase (FAK) is an emerging target for cancer chemotherapy with mounting evidence that FAK activation or elevated expression is associated with cancer progression, invasion, and drug resistance. This work envisages identification and in silico screening of potential FAK inhibitors which could further be evaluated. A total of 862 compounds were screened from the ZINC database and docked on the refined FAK enzyme using Autodock Vina. The best spotted hits were filtered for their druglikeness using SwissADME. These potential hits were further evaluated for their in silico toxicity using ProTox II software. Promiscuous hits identified by the docking score and applying Lipinski's Rule of five were ZINC43200601, ZINC95593660 and ZINC95595125. These hits showed high binding scores and passed the colander of in silico pharmacokinetic and toxicity proving these ligands propitious to be further evaluated. For selecting the Activity Spectra for Substances PASS program was used to screen the anticancer potential of the compound. The hits displayed antitumor profile. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-066866 | Impact of pH on the antibacterial activity of Norfloxacin in its combined use with Oxalic Acid against Escherichia coli ATCC 25922 | , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
The bacterial susceptibility and the translocation of fluoroquinolones (FQs) are influenced by pH, since it determines the proportion of microspecies of the drug. Norfloxacin (NOR) and Oxalic Acid (AO) are antibacterial compounds. In this work, we evaluated the antibacterial activity of the NOR-AO combination on the Escherichia coli ATCC 25922 strain using the checkerboard method. Besides, we analyzed the pH effect on the NOR-AO combination. We determined the extent of NOR ionization equilibrium and calculated the apparent log P to establish the lipophilicity of NOR at the different pHs assayed. The minimum inhibitory concentration (MIC) obtained for AO and NOR was 1250 µg/mL and 0.25 µg/mL, respectively. The interaction of NOR-AO was indifferent in the concentrations worked (CIF 1.12). However, an atypical behavior was observed in E.coli growth. We observed that at pH values <5.8 and log D < -0.3, the cationic species of NOR predominates, decreasing its activity. As pH increases, the predominant species is zwitterionic with increased lipophilicity and restoration of NOR activity. Therefore, the acid conditions given by the presence of AO decrease the concentration of the neutral species of NOR and therefore the amount of drug capable of diffusing directly through the membrane. There is controversy in the literature regarding the mechanism of FQs translocation through the bacterial membrane, however, our results show that the pH of the medium is a determining factor that directly impacts the antibacterial activity. To deepen this study, we will continue testing new concentrations and combinations with other organic acids. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-065705 | Patient-centric drug product design: case studies for special populations |
![]() |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Medication non-adherence poses considerable challenges in managing chronic diseases and is associated with almost 200,000 deaths and €80-125 billion of potentially preventable direct (e.g. hospitalizations, waste of medication) and indirect (e.g. work productivity losses) costs in the European Union alone. The increasing awareness of the contribution of the acceptability of drug products by the patient to medication adherence and clinical outcomes is driving the integration of Patient Centric drug Product Design (PCDPD) into the pharmaceutical development process. Regulatory agencies have addressed the relevancy of placing the patient in the center of pharmaceutical development. EMA has issued guideline/reflection papers for pediatric and older populations while FDA has developed a series of guidance documents on patient focused drug development with the primary goal to better incorporate the patient’s voice in drug development and evaluation. PCDPD can be defined as the process of identifying the comprehensive needs of the target patient population to support the design of drug products. Three major factors are analyzed in PCDPD, namely patient, drug and drug product characteristics. This systematic approach integrates this insight which is translated to a Target Product Profile (TPP) to drive the pharmaceutical product design process. Two case studies will be presented focused on the pediatric population and on patients with a chronic skin disorder (psoriasis) which will highlight the roadmap for a successful PCDPD. |
Keynote Presentations
-
Patient-centric drug product design: case studies for special populations
By
-
In the heart of cardio-oncology: the targets and biomarkers of anticancer drugs cardiotoxicity
By
-
Small molecule inhibitors of bacterial quorum sensing
By
-
By
, , , -
A potential blueprint for the design of biased ligands for aminergic GPCRs
By
-
C-Glucosyl Flavone Derivatives as Non-PAIN Therapeutic Leads for Alzheimer’s Disease
By
-
A Chemical Strategy to Improve Bioavailability of Glypromate Peptide-Conjugates
By
, ,Hugo F. Costa-Almeida, , ,José E. Rodríguez-Borges -
Resveratrol-loaded glycosylated liposomes for targeting bacteria
By
, , , , , , , , , , , , , , , -
In the heart of cardio-oncology: the targets and biomarkers of anticancer drugs cardiotoxicity
By
-
Virtual screening and drug repurposing: together against worm-borne diseases
By
, , , ,Yujie Sun,Dilini Amarasinghe, ,Vitor de Alme Almeida, -
The combined use of AuNP and NIR radiation enables cytosolic protein delivery
By
, , ,Anna Lladó,Pere Serra,Dobryna Zalvidea, ,
Welcome from the Chairs
Dear Colleagues,
Following the great success of the previous editions organized under the excellent chairmanship of Dr. Jean Jacques Vanden Eynde, we are pleased to cordially invite you to join us at 8th International Electronic Conference on Medicinal Chemistry, sponsored by the MDPI open access journal Pharmaceuticals. This platform seeks to provide a discussion forum for scientists from all over the world for recent developments and innovative ideas in Medicinal Chemistry. This will give students, researchers, and experts the opportunity to share their latest theories, results, models, and applications in this multidisciplinary area of knowledge. This is an entirely on-line conference that will be held during the month of November at https://ecmc2022.sciforum.net/. No registration fee is charged to participants, and there is the added advantage that there is no cost of flights, hotels, etc.
The conference will be organized around the aims and scope of the journal Pharmaceuticals, which include the following general topics:
Small molecules as drug candidates
Biomolecules, natural products, phages, and cells as therapeutic tools
Biological targets and biomarkers
Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
Pharmacokinetics and pharmacodynamics
Pharmaceutical preparations and drug delivery
The format of the conference is as follows. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://sciforum.net/user/submission from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract, at which point they will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, open for discussion, comments, and questions, during the entire conference, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
All participants will be invited to submit a full paper describing their work, which would be peer reviewed and, upon acceptance, published in a Special Issue “Selected Papers from the 8th International Electronic Conference on Medicinal Chemistry (ECMC2022)” covering the event in Pharmaceuticals (ISSN 1424-8247) sponsor of the conference. A 20% discount on the Article Processing Charge will be applied.
The most outstanding works, as selected by the scientific committee, will be rewarded with grants offered by the sponsoring journal Pharmaceuticals.
We look forward to engaging in exciting discussions and hearing new ideas and perspectives from experts in the field. All participants are welcome to join the online conference.
Kind regards,
Dr. Alfredo Berzal-Herranz
Prof. Dr. Maria Emília Sousa
Call for Participations
The members of the Scientific Committee are pleased to announce this Call for Participation for the 8th International Electronic Conference on Medicinal Chemistry and to invite each researcher working in the exciting fields of medicinal chemistry and drug-related sciences to share their recent results with their colleagues all over the world.
The Conference will cover a wide range of aspects involved in drug discovery and development. A non-exhaustive list of topics that will be considered includes:
- ADMET
- Animal experimentation
- Assay development
- Biomarkers
- Biomolecules
- Biosensors
- Biotechnology
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro and in vivo studies
- Lead optimization
- Omics
- Pharmaceutical analysis
- Scale-up
- Structure–activity relationships
Participation in the 8th International Electronic Conference on Medicinal Chemistry is absolutely free of charge for contributors and visitors. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://www.sciforum.net/login from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. Authors will be notified before 1 October with regard to the acceptance status of their abstract, at which point the author(s) will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
Authors will be invited to publish their work as a review or a research article at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the Pharmaceuticals editorial office at [email protected].
We thank you in advance for your attendance to this conference and look forward to a stimulating exchange.
Submission Guidelines
For information about the submission procedure and the preparation of a full presentation, please refer to the "Instructions for Authors".
Event Chairs

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain

Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
Event Committee

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Portugal

Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Sweden

Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, Germany

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany

Department of Pathology & Microbiology, University of Nebraska Medical Center, USA

Center of Health Sciences, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, Brazil

Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland

Department of Pharmacy, University of Chieti, Italy

Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, 800 Buchanan St., Albany, CA 94710, USA

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Granada, Spain

Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Italy

Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Portugal

Department of Biomolecular Sciences, University of Urbino Carlo Bo Piazza del Rinascimento, Italy

Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Turkiye
Invited Speakers

Institute for Biological System, Secondary office of Rome-Reaction Mechanisms, c/o Chemistry Dept Sapienza University of Rome, Italy

Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Portugal

Grupo de Pesquisas Químico-Farmacêuticas, GPQFfesp, Chemical and Pharmaceutical Sciences, Institute of Environmental, Federal University of São Paulo, Brazil

Department Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville, USA

Microbiology and Infectious Diseases, School of Systems Biology, George Mason University, USA

Theoretical Medicinal Chemistry, Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany

Group of Receptor Ligands for Molecular Imaging, European Institute for Molecular Imaging (EIMI), Muenster University, Germany

Group of Chemical biology of peptides and proteins, Department of Molecular Biology, Instituto de Parasitologia y Biomedicina "Lopez-Neyra" Spain

UCIBIO/REQUIMTE, Associate Laboratory i4HB - Institute for Health and Bioeconomy, MedTech-Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal

IQ, Laboratório de Modelagem Molecular (LabMMol) - Sala 609, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, Brazil

School of Pharmacy and School of Chemistry, University College Cork, Ireland

Docent in Structural Biology and Computational Biochemistry, Pharmaceutical Sciences Laboratory & Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland

School of Chemistry, Trinity College Dublin, Ireland

UCIBIO-REQUIMTE, Rede de Química e Tecnologia,Porto University, Portugal
Instructions for Authors
Submission should be completed online by the authors by registering with https://sciforum.net/ and using the “Start New Submission” function once logged into the system.
- Scholars interested in participating in the conference can submit their abstract (250 words maximum without figures and without references) online at this website until 21 September 2022 30 September 2022.
- Based on the submitted abstract, the conference committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for 8th International Electronic Conference on Medicinal Chemistry. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience, until the submission deadline of 12 October 2022.
- Posters must be uploaded as a PDF file using the Poster_template.pptx file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT_template.pptx file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT_template.pptx file available at the end of this section.
- Tips for authors: if you would like to prepare a video based on your PowerPoint presentation, you may use the "record slide" function in PowerPoint.
This must be uploaded before 12 October 2022, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the Conference Office.
Contributions will be displayed on the website using Sciforum.net’s proprietary slides viewer and will be accessible at https://ecmc2022.sciforum.net/ at the time of the conference. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Contributions must be converted to PDF format before submission, so that they can be easily and automatically converted to be displayed online.
The organization of posters is left completely up to the authors, provided that they use the conference’s template.
The accepted contributions will probably be published as one dedicated volume in the MDPI Medical Sciences Forum journal. Publication of proceedings paper is free of charge.
Note: Before publication, Medical Sciences Forum journal will review accepted papers using the powerful text comparison tool: iThenticate. This procedure aims to prevent scholarly and professional plagiarism.
Submissions with a high repetition rate and lack of novelty will not be published in the conference proceedings.
Certificate of Attendance : After the event, the participants of ECMC 2022 will be able to download an electronic Certificate of Attendance by logging in to your Sciforum personal account. Once you are logged-in, go to your profile and click on 'My certificates'. A list of all Sciforum events you have attended is available and you simply have to click on "Download" next to the correct event.
We recommend the following organization for your slideshow, poster or video, using the Conference’s template:
Slides- Length of the presentation: no more than 30 slides
- Slides can be prepared the same way as for any traditional conference. They should be converted into a PDF format before submission.
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper.
The poster should be in PDF format
- The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
- The content of the poster should be a comprehensive presentation of your accepted submission.
- No copyright issues with any elements in the poster.
Uploaded files:
Event Awards
The following awards will be offered by our organizers.
The Awards
The open access peer-reviewed Journal Pharmaceuticals will offer each one award (400 CHF) to reward the best poster, the best slideshow, the best flash communication and the best communication, and 500 CHF to reward the best invited lecture. All submissions will be considered, independently of the session (general and round table). The best works will be selected by the members of the Scientific Committee.
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.
Conference Secretariat
Ms. Amber Zhao
Ms. Jennifer Wang
Email: [email protected]
S1. Opening session

Prof. Dr. Maria Emília Sousa

Dr. Alfredo Berzal-Herranz
S2. Invited lectures

Prof. Dr. Maria Emília Sousa

Dr. Alfredo Berzal-Herranz
S3. General

Dr. Jong Heon Kim
S4. Small molecules as drug candidates

Prof. Dr. Mary J. Meegan

Dr. Daniela De Vita
S5. Biomolecules as therapeutics

Prof. Dr. Amélia Pilar Rauter

Dr. Cristina Romero-López
S6. Emerging technologies in drug discovery

Prof. Dr. Joachim Jose

Prof. Dr. Osvaldo Andrade Santos-Filho
S7. Radiopharmaceuticals

Dr. Klaus Kopka
S8. Pharmaceutical development

Prof. Dr. Jessica Rosenholm
Winner Announcement
On behalf of the chairs of the 8th International Electronic Conference on Medicinal Chemistry (ECMC-8), we are pleased to announce the winners of the Conference Award:
Best Poster Award
- Marie Hanot et al., "Development of New Anti-virulence Agents to Tackle Multi-resistant Pseudomonas Aeruginosa".
Marie Hanot is a second-year Ph.D. student in Medicinal Chemistry, in the team of Pr. Pascal Sonnet (AGIR, UR4294) at the Faculty of Pharmacy of the University of Picardie Jules Verne (France). Marie’s research focuses on the development of anti-virulence agents to combat pseudomonal multi-drug resistance. Marie holds a B.Sc. degree in chemistry from the same institution as well as a M.Sc. degree in Chemistry, Biology and Drugs from the University of Strasbourg (France).
Best Slideshow Award
- Maddalena Paolillo et al., "Binding to Proteins of the Pharmacologically Active Bis(Maltolato) Oxidovanadium(IV)".
The presenting author, Maddalena Paolillo, is a first-year Ph.D. student in Chemical Sciences from Department of Chemical Sciences of University of Naples Federico II (Italy). She is working under the supervision of Prof. Antonello Merlino and Prof. Filomena Sica.
She holds a master’s degree in chemical sciences (2022), with a thesis on the refinement of crystal structures of adducts formed upon reaction of model proteins with a vanadium compound of medical interest. The topic of her Ph.D. is focused on the study of the mechanism of action of different V-based drugs by analyzing, both in solution and at solid state, their interaction with biological macromolecules.
Best Flash Communication Award
- Fabian Krutzek et al., "Small Molecule Radiotracers for PET Imaging of PD-L1 with Copper-64”.
Fabian Krutzek studied Chemistry at the University of Heidelberg and obtained 2019 his Master degree in organic chemistry. Currently he is a fourth-year PhD student at the Helmholtz Center Dresden-Rossendorf under supervision of Prof. Dr. Klaus Kopka. His research project focuses on design, synthesis, and evaluation of small molecule-based radiotracers for imaging PD-L1 in cancer patients. This project requires a high level of synthetic organic chemistry, with up to 25 synthetic steps per molecule. In the interdisciplinary field of medicinal radiochemistry, he developed skills in radiochemical labeling and obtained basic knowledge in computational methods as well as cell-based assays. Through collaboration with biologists, he gained theoretical knowledge on the conduction and analysis of data from animal studies. Currently in the final months of his Ph.D. studies, he plans to pursue post-doctoral studies abroad in a related field of organic chemistry.
Best Communication Award
-Ana Marta de Matos et al., "C-Glucosyl Flavone Derivatives as Non-PAIN Therapeutic Leads for Alzheimer’s Disease".
Ana Marta de Matos graduated in Biochemistry in 2011 at FCUL and completed her M.Sc. degree in Medicinal Chemistry at FFUL in 2013. She then returned to FCUL where she pursued her Ph.D. in Organic Chemistry with a focus on the synthesis and biological evaluation of new sugar-based polyphenols with bioactivity against type 2 diabetes and Alzheimer’s disease. During her path as a Ph.D. student, she spent nine months at Eli Lilly’s Neuroscience Research Centre in Windlesham, UK, where she worked closely with some of the best Medicinal Chemists in the World. She completed her Ph.D. in 2019, published her results in high-quality peer-reviewed scientific journals in the field, and won the FCiências.ID award for Best Ph.D. Thesis in Chemistry in 2019. In July 2021, Ana received a research contract to initiate her career as an independent researcher at Centro de Química Estrutural (CQE), from the Institute of Molecular Sciences (IMS), FCUL. One year later, she was awarded a contract in the highly competitive FCT call 'Scientific Employment Stimulus 2022’, having also been nominated as shadow coordinator of the Carbohydrate Chemistry Group of CQE, FCUL. Ana Marta is currently interested in developing new carbohydrate-based compounds against infections caused by multidrug-resistant Gram-negative bacteria.
Best Invited Lecture Award
Dr Tim O’Sullivan received his BSc Degree in Industrial Chemistry from the University of Limerick in 1997. He then went on to do a PhD in natural products synthesis under the supervision of Prof. Lew Mander at the Research School of Chemistry of the Australian National University from 1998 to 2001. He worked as a postdoctoral researcher on the synthesis of Tamoxifen analogues with Prof. Mary Meegan in Trinity College Dublin from 2001 before taking up another postdoctoral fellowship with Prof. Pat Guiry in University College Dublin on the synthesis of novel Lipoxin analogues in 2003 . Following a period as research manager in UCD, he was appointed as Lecturer in Pharmaceutical Chemistry in the School of Pharmacy/Department of Chemistry/ABCRF in UCC in 2006. He is a member of the Royal Society of Chemistry, the Marie Curie Alumni Association and COST Action 'CA21145 European Network for diagnosis and treatment of antibiotic-resistant bacterial infections (EURESTOP)'. His research is focussed on developing new methods and strategies for the synthesis of bioactive, natural products. The underlying goal in this work is to improve upon existing techniques and to discover novel methods for assembling complex molecular targets. The ultimate aim is to apply this knowledge to the development of more potent analogues of existing compounds, with a view to producing pharmaceutically relevant therapeutic agents.
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting
-Rosa Tundis et al., "In vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy ".
-Maria Mernea et al., "A molecular docking study on natural compounds as anxiolytics and antidepressants ".
S2. Invited lectures
Show all published submissions (10) Hide published submissions (10)
Submissions
List of Papers (10) Toggle list
S4. Small molecules as drug candidates
S5. Biomolecules as therapeutics
S6. Emerging technologies in drug discovery
S7. Radiopharmaceuticals
Show all published submissions (3) Hide published submissions (3)
Submissions
List of Papers (3) Toggle list